JPRN-UMIN000043350已完成未知
Elucidation of immune response behavior and factors by COVID-19 vaccination - COVID-19 vaccination/ immune response program
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 51
研究概览
简要总结
Interim analysis results up to 2 weeks after the third vaccination (peak phase) were published in Vaccines 2022, 10(7), 1050; https://doi.org/10.3390/vaccines10071050'. We have clarified the behavior of long-term humoral and cell-mediated immunity against SARS-CoV-2 and characterized the antibody assay system. We are currently analyzing the behavior in the third/fourth vaccination (booster).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Those who cannot tolerate multiple blood draws due to thin blood vessels. 2.Those who have difficulty collecting blood and have strong pain. 3.Those with a history of vasovagal reflex. 4.Those who have already been vaccinated with COVID-19 vaccine.
研究者
相似试验
已完成
4 期
A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza SeasonInfluenzaNCT01457027Crucell Holland BV52
Unknown
4 期
Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated VaccinesCOVID-19NCT05095298Huashan Hospital400
已完成
3 期
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa VaccinationDiphtheriaPoliomyelitisHaemophilus Influenzae Type bHepatitis BTetanusWhooping CoughNCT01983540Sanofi Pasteur, a Sanofi Company558
已完成
1 期
Immunogenicity Assessment Extension Study of nCoV-2019novel coronavirus vaccine developed by Cadila Healthcare Ltd inPhase I part of Protocol NCOV 1002.CTRI/2021/02/031451Cadila Healthcare Ltd18
已完成
2 期
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsEncephalitis, Tick-borneNCT00161850Pfizer615